Clinical Trial

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cell Carcinoma (RCC), or Melanoma
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2022-12-15; most recent amendment 2026-05-08.
Status change: Recruiting → Active, Not Recruiting 2025-04-07
Status change: Not Yet Recruiting → Recruiting 2023-04-21
Trial Details
NCT Number NCT05661955
Lead Sponsor BeiGene
Conditions Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
Enrollment 113 participants
Start Date 2023-01-09
Primary Completion 2025-05-27 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-11